<DOC>
	<DOCNO>NCT00427882</DOCNO>
	<brief_summary>Primary : To assess improvement ejaculation baseline end treatment ( Week 12 premature withdrawal ) Alfuzosin 10mg OD , use MSHQ score . Secondary : - To evaluate sexual function improvement - To evaluate LUTS ( Lower Uninary Tract Symptoms ) improvement - To evaluate association LUTS severity sexual function . - To assess safety tolerability Alfuzosin 10mg OD .</brief_summary>
	<brief_title>Male Sexual Health Questionnaire ( MSHQ ) - Sexual Function Study</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Alfuzosin</mesh_term>
	<criteria>Patients suffer moderate severe low urinary tract symptom ( LUTS ) , suggestive symptomatic Benign Prostatic Hyperplasia ( BPH ) diagnose Investigator Patients IPSS total score ≥ 8 Patients sexually active define least one follow activity last 4 week : intercourse , caress , foreplay , masturbation Patients know history hepatic severe renal insufficiency , unstable angina pectoris Patients previous prostate surgery Patients prostate biopsy minimally invasive procedure within 6 month prior inclusion Patients prostate surgery minimally invasive procedure whole study period Patients active urinary tract infection prostatitis Patients neuropathic bladder define spinal injury consequence related neurological disorder know residual volume ≥ 350 ml Patients diagnosed prostate cancer Patients receive 5areductase inhibitor LUTS relatedphytotherapy within 6 month prior inclusion , a1blockers within 30 day prior inclusion Patients receive treatment erectile dysfunction ( i.e . phosphodiesterase5 inhibitor ) inclusion Patients history postural hypotension syncope Patients know hypersensitivity alfuzosin The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>